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CHAPTER I 
 
Introduction 
 
Anaesthesia for Functional endoscopic sinus surgery is a challenging 
job. The surgeons’ operating field itself is very small and surrounded with mucus 
membranes. It is imperative for the surgeons to look at a clear surgical field in 
order to identify the diseased tissue properly. A small amount of blood within the 
field is enough to occlude the view through the endoscope making things difficult 
for the surgeon, and incomplete removal of the diseased tissue will cause the 
disease to reoccur. Anaesthesiologists have devised various techniques to prevent 
this bleeding, of which induced hypotension has stood the test of time. This 
surgery per se is not a major one by its standards and surgeons recently have been 
trying to accomplish FESS as a daycare surgery. A good premedication with an 
antihypertensive agent can help to minimize the amount of volatile agents and 
vasodilators used to induce hypotension, thereby ensuring much hemodynamic 
stability and speedy recovery from anaesthesia. Thus I have chosen to study and 
compare the effects of clonidine and atenolol as oral premedicants for the same.  
This study proposes to analyze the anaesthetic challenge of keeping 
the operating field free of blood through pharmacological therapy. It compares 
how premedicating with either atenolol or clonidine affects the conduct of the 
fixed anaesthesia protocol evolved in our institute on patients undergoing FESS 
procedure under GA, and requiring a hypotensive technique to improve operating 
conditions. 
 
 
CHAPTER II 
 
Hypotensive anesthesia 
 
Hypotensive anesthesia is a technique, used intraoperatively to help 
minimize surgical blood loss, thereby decreasing the need for blood transfusion 
and also to provide a clear surgical field.  The technique entails the controlled 
lowering of blood pressure and is defined as a reduction of the systolic blood 
pressure to between 80-90 mmHg. An alternative definition is a decrease in mean 
arterial pressure (MAP) to 50-70 mmHg in a normotensive patient. 
 
Inducing hypotension 
  
Deliberate hypotension is induced by a variety of pharmacological 
agents and nonpharmacological methods. Since there is no single agent capable of 
safely and effectively lowering arterial pressure in all situations, the anesthetist 
may need to employ a variety of agents or techniques in order to achieve the target 
pressure.   
Pharmacological agents can generally be divided into two 
categories: peripheral vasodilators and inhalation agents.   
The three most commonly used vasodilators are: sodium nitroprusside (SNP), 
nitroglycerin (NTG), and trimethaphan.    
SNP acts as a vascular smooth muscle relaxant and has a rapid onset but brief 
duration of action. Its primary influence is on arteriolar and venous vessels, but 
without significant myocardial effects.   
NTG reduces blood pressure by relaxing venous smooth muscle and, like SNP, has 
rapid onset of action but short duration. NTG is less toxic than SNP; however, it is 
less potent than SNP in its capacity to reduce blood pressure.   
Trimethaphan produces hypotension through ganglionic blockade and direct 
vasodilator properties. It is also short acting and provides tight control of blood 
pressure. 
Commonly used inhalation agents, or volatile anesthetic agents, include halothane 
and isoflurane. The concentration of a volatile anesthetic agent produces a dose-
dependent decrease in mean arterial pressure. 
Alpha2 agonists and beta blockers are also used for this purpose.   
Spinal and epidural anesthesia can also be used to produce controlled hypotension. 
Unfortunately, these techniques require large infusions of fluids and the deliberate 
hypotension can be erratic and difficult to control. 
 
 
 
 
Indications to Hypotensive Anaesthesia 
• Excision of intracranial tumors 
• Aneurysm excisions ( Cerebral, Carotid, Aortic) 
• FESS procedure 
• Middle ear surgeries 
• Spine / hip surgeries 
 
Contraindications to Hypotensive Anaesthesia 
• Congenital heart disease  
• Severe anemia  
• Coronary artery disease  
• Congestive heart failure  
• Poorly controlled hypertension  
• Increased intracranial pressure  
• Significant cerebro-vascular disease  
• Low flow states to the liver or kidney 
 
 
 
 
 
 
 
CHAPTER III 
 
Functional Endoscopic Sinus Surgery 
 
Rhinology and sinus surgery have undergone a tremendous 
expansion since the discourses of Messerklinger and Wigand in the late 1970s. 
Imaging advances, increased understanding of the anatomy and the 
pathophysiology of chronic sinusitis, and image-guided surgery have allowed 
surgeons to perform more complex procedures with increased safety.  
Functional endoscopic sinus surgery is the primary approach used 
today for the surgical treatment of chronic sinusitis.  
Indications 
Endoscopic sinus surgery is most commonly performed for 
inflammatory and infectious sinus disease. The most common indications for 
endoscopic sinus surgery are as follows:  
• Chronic sinusitis refractory to medical treatment  
• Recurrent sinusitis  
• Nasal polyposis  
• Antrochoanal polyps  
• Sinus mucoceles  
• Excision of selected tumors  
• Cerebrospinal fluid (CSF) leak closure  
• Orbital decompression (e.g., Graves ophthalmopathy)  
• Optic nerve decompression  
• Dacryocystorhinostomy (DCR)  
• Choanal atresia repair  
• Foreign body removal  
• Epistaxis control 
 
FESS is a delicate and time consuming procedure; it is performed 
routinely under general anaesthesia. Anaesthesiologists have to plan the technique 
in such a way that will facilitate the operating team for achieving a bloodless field 
for better visualization of the intranasal structures and minimise intraoperative 
bleeding, because even minimal bleeding can obstruct the view of the operating 
endoscope. Hence comes the role of hypotensive anaesthesia. Many 
pharmacological agents, including isoflurane as a combination, are in use for 
inducing intraoperative hypotension. It is easy to administer and control its 
concentration, does not require infusion pump and can be quickly washed out from 
body by hyperventilation. As isoflurane induces hypotension slower than the other 
pharmacological agents like sodium nitroprusside, continuous intra-arterial blood 
pressure monitoring is not mandatory. It causes least arrhythmia in presence of 
exogenous adrenaline which is routinely infiltrated into the operative field for 
creating a bloodless field. 
CHAPTER IV 
PHARMACOLOGY OF THE STUDY DRUGS 
 
Clonidine: 
 
Clonidine hydrochloride USP is a centrally acting antihypertensive 
agent available as tablets for oral administration in three dosage strengths: 0.1 mg, 
0.2 mg and 0.3 mg. The 0.1 mg tablet is equivalent to 0.087 mg of the free base. 
Clonidine hydrochloride is an imidazoline derivative and exists as a 
mesomeric compound. The chemical name is 2-(2,6-dichlorophenylamino)-2- 
imidazoline hydrochloride. It has the following molecular formula: C9H9CI2N3 • 
HCl, with molecular weight of 266.56. its structural formula is: 
 
 
Pharmacokinetics and Metabolism 
 
Clonidine hydrochloride is an odorless, bitter, white, crystalline 
substance soluble in water and alcohol. Clonidine hydrochloride acts relatively 
rapidly. Following oral administration about 40-60% of the absorbed dose is 
recovered in the urine as unchanged drug in 24 hours. The patient's blood pressure 
declines within 30 to 60 minutes after an oral dose, the maximum decrease 
occurring within 2 to 4 hours. The plasma level of clonidine hydrochloride peaks 
in approximately 3 to 5 hours and the plasma half-life ranges from 12 to 16 hours. 
About 50% of the absorbed dose is metabolized in the liver. 
 
Pharmacodynamics 
Clonidine stimulates alpha-adrenoreceptors in the brain stem, 
resulting in reduced sympathetic outflow from the central nervous system and a 
decrease in peripheral resistance: at a 45° tilt there is a smaller reduction in cardiac 
output and a decrease of peripheral resistance. During long-term therapy, cardiac 
output tends to return to control values, while peripheral resistance remains 
decreased. Slowing of the pulse rate has been observed in most patients given 
clonidine, but the drug does not alter normal hemodynamic response to exercise. 
It also causes a reduction in plasma renin activity and in the excretion of 
aldosterone and catecholamines. Tolerance may develop in some patients. 
  
Dosage and administration 
Adults: The dose of clonidine hydrochloride must be adjusted according to the 
patient's individual blood pressure response.  
Initial Dose: 0.1 mg tablet twice daily (morning and bedtime). Elderly patients 
may benefit from a lower initial dose. 
Maintenance Dose: Further increments of 0.1 mg per day may be made if 
necessary until the desired response is achieved. The therapeutic doses most 
commonly employed have ranged from 0.2 mg to 0.6 mg per day given in divided 
doses. 
Renal Impairment: Dosage must be adjusted according to the degree of 
impairment, and patients should be carefully monitored. Half life in such patients 
may extend up to 41 hours. 
 
Side effects 
Most adverse effects are mild and tend to diminish with continued 
therapy. The most frequent (which appear to be dose-related) are dry mouth, 
drowsiness, dizziness, constipation and sedation. 
 
Drug interactions 
If a patient receiving clonidine hydrochloride is also taking tricyclic 
antidepressants, the effect of clonidine may be reduced. Clonidine hydrochloride 
may enhance the CNS-depressive effects of alcohol, barbiturates or other 
sedatives. 
 
Withdrawal: Sudden cessation of clonidine treatment, regardless of the route of 
administration, hours in some cases, resulted in symptoms such as nervousness, 
agitation, headache, and tremor, accompanied or followed by a rapid rise in blood 
pressure. Rebound hypertension following abrupt withdrawal has been extensively 
reported. 
 
Precautions 
Clonidine hydrochloride should be used with caution in patients with 
severe coronary insufficiency, recent myocardial infarction, cerebrovascular 
disease or chronic renal failure. 
 
Perioperative Use 
Administration of clonidine hydrochloride should be continued to 
within four hours of surgery and resumed as soon as possible thereafter. The blood 
pressure should be carefully monitored and appropriate measures instituted to 
control it as necessary. 
 
Overdose 
The signs and symptoms of clonidine hydrochloride over dosage 
include hypotension, bradycardia, lethargy, irritability, weakness, somnolence, 
diminished or absent reflexes, miosis, vomiting and hypoventilation. 
 
Contraindications 
None known. 
 
 
 
 
 
 
 
 Atenolol 
 
Atenolol, a synthetic, beta1-selective (cardioselective) 
adrenoreceptor blocking agent, may be chemically described as benzeneacetamide, 
4 -[2'-hydroxy-3'-[(1- methylethyl) amino] propoxy]-. The molecular and 
structural formulas are: 
 
 
Atenolol is available as 25, 50 and 100 mg tablets for oral administration. 
Atenolol is a beta1-selective (cardioselective) beta-adrenergic 
receptor blocking agent without membrane stabilizing or intrinsic 
sympathomimetic (partial agonist) activities. This preferential effect is not 
absolute, however, and at higher doses, atenolol inhibits beta 2 - adrenoreceptors, 
chiefly located in the bronchial and vascular musculature. 
 
Pharmacokinetics and Metabolism  
In man, approximately 50% of an oral dose is absorbed from the 
gastrointestinal tract, the remainder being excreted unchanged in the feces. Peak 
blood levels are reached between two (2) and four (4) hours after ingestion. 
Atenolol undergoes little or no metabolism by the liver, and the absorbed portion 
is eliminated primarily by renal excretion. Over 85% of an intravenous dose is 
excreted in urine within 24 hours compared with approximately 50% for an oral 
dose. 
The elimination half-life of oral atenolol is approximately 6 to 7 
hours, and there is no alteration of the kinetic profile of the drug by chronic 
administration. Following intravenous administration, peak plasma levels are 
reached within 5 minutes. Declines from peak levels are rapid (5- to 10-fold) 
during the first 7 hours; thereafter, plasma levels decay with a half-life similar to 
that of orally administered drug. 
 
Pharmacodynamics  
The beta-adrenoreceptor blocking activity of atenolol has been 
demonstrated by: (1) reduction in resting and exercise heart rate and cardiac 
output, (2) reduction of systolic and diastolic blood pressure at rest and on 
exercise, (3) inhibition of isoproterenol induced tachycardia, and (4) reduction in 
reflex orthostatic tachycardia.  
This effect is maximal at about 2 to 4 hours, and persists for at least 
24 hours. Maximum reduction in exercise tachycardia occurs within 5 minutes of 
an intravenous dose. By blocking the positive chronotropic and inotropic effects of 
catecholamines and by decreasing blood pressure, atenolol generally reduces the 
oxygen requirements of the heart at any given level of effort. Atenolol can 
increase oxygen requirements by increasing left ventricular fiber length and end 
diastolic pressure, particularly in patients with heart failure. 
 
Indications and Usage 
Hypertension  
Angina Pectoris Due to Coronary Atherosclerosis 
Acute Myocardial Infarction  
 
Dosage and Administration 
Hypertension  
The initial dose of atenolol is 50 mg given as one tablet a day either alone or 
added to diuretic therapy. If an optimal response is not achieved, the dosage 
should be increased to atenolol 100 mg given as one tablet a day.  
Extra care to be exercised when prescribing beta blockers in patients with CCF, 
DM, Hypoglycemia and COPD. 
 
Anesthesia and Major Surgery  
It is not advisable to withdraw beta-adrenoreceptor blocking drugs 
prior to surgery in the majority of patients. However, care should be taken when 
using anesthetic agents such as those which may depress the myocardium. Vagal 
dominance, if it occurs, may be corrected with atropine (1-2 mg IV).  
Atenolol, like other beta blockers, is a competitive inhibitor of beta-receptor 
agonists and its effects on the heart can be reversed by administration of such 
agents: e.g., dobutamine or isoproterenol with caution. 
 
Overdose 
The predominant symptoms reported following Atenolol overdose 
are lethargy, disorder of respiratory drive, wheezing, sinus pause, bradycardia, 
congestive heart failure, hypotension, bronchospasm and/or hypoglycemia.  
Treatment of overdose should be directed to the removal of any 
unabsorbed drug by induced emesis, gastric lavage, or administration of activated 
charcoal. Atenolol can be removed from the general circulation by hemodialysis. 
Other treatment modalities should be employed at the physician's discretion and 
may include:  
BRADYCARDIA: Atropine intravenously. If there is no response to vagal 
blockade, give isoproterenol cautiously. In refractory cases, a transvenous cardiac 
pacemaker may be indicated.  
HEART BLOCK (SECOND OR THIRD DEGREE): Isoproterenol or transvenous 
cardiac pacemaker. 
CARDIAC FAILURE: Digitalize the patient and administer a diuretic. Glucagon 
has been reported to be useful.  
HYPOTENSION: Vasopressors such as dopamine or norepinephrine 
(levarterenol). Monitor blood pressure continuously.  
BRONCHOSPASM: A beta2 stimulant such as isoproterenol or terbutaline and/or 
aminophylline.  
HYPOGLYCEMIA: Intravenous glucose.  
Based on the severity of symptoms, management may require intensive support 
care and facilities for applying cardiac and respiratory support.  
CONTRAINDICATIONS  
Atenolol is contraindicated in sinus bradycardia, heart block greater than first 
degree, cardiogenic shock, and overt cardiac failure. 
Atenolol is contraindicated in those patients with a history of hypersensitivity to 
the atenolol or any of the drug product’s components. 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER V 
REVIEW OF LITERATURE 
This study was constructed to evaluate if clonidine and atenolol 
premedication offers any advantage for the conduct of hypotensive anaesthesia 
technique for patients undergoing FESS procedure under GA. The Null hypothesis 
postulated for testing was such premedication would offer superior hemodynamic 
stability and decrease the need of vasoactive drugs to decrease the BP to the 
desired level. Literature was reviewed to analyze the existence of similar studies. 
 
Maroof et al7, in their study on ‘Clonidine premedication for induced hypotension 
with TIVA for middle ear microsurgery’ recruited 30 ASA I or II adult patients 
and surgery done using TIVA with Propofol and fentanyl. Group I received 
meperidine and promethazine, group II received clonidine 4mcg/kg with 
meperidine and promethazine. They found that addition of clonidine 
premedication with TIVA can provide stable hypotensive anaesthesia with 
minimum labetalol requirements. 
 
Mikawa et al8, in their study ‘Attenuation of catecholamine response to tracheal 
intubation with oral clonidine’ recruited 105 ASA I children in a randomized 
double blind study and have shown that tracheal intubation caused an increase in 
plasma catecholamine concentrations, blood pressure and heart rate in children 
receiving diazepam, and that clonidine 4mcg/kg PO blunted these changes. 
Attenuation of the pressor and tachycardic responses to tracheal intubation with an 
oral high dose of clonidine could be due at least in part due to suppression of 
catecholamine release. 
 
Buggy et al4, in their study on ‘ Clonidine at induction reduces shivering after 
general anaesthesia’ used 60 ASA I or II patients scheduled for orthopedic limb 
surgeries into two groups, one receiving clonidine 150 mcg i.v. and the other 
group saline i.v. They found that clonidine at the induction of anaesthesia reduces 
shivering. 
 
Bellaiche et al6, in their study on ‘Clonidine does not delay recovery from 
anaesthesia’ studied 46 ASA I or II undergoing thyroid surgery. Patients were 
randomly allocated into three groups and 2 hours before surgery received 
flunitrazepam 1 mg orally (group I), clonidine 150 mcg (group II), both (group 
III). Anaesthetic procedure was same for three groups. There was no difference 
between the three groups in regard to recovery characteristics. 
 
Nicolaou et al14, in their study on ‘Clonidine decreases vasoconstriction and 
shivering threshold without affecting the sweating threshold’ took 6 subjects who 
were studied for 4 days after taking oral clonidine of either 0, 3, 6 or 9 mcg/kg. 
The study was designed in a double blind fashion. They found out that the 
decreases in core temperature thresholds for cold responses and increased inter 
threshold range are consistent with the effects of several anaesthetic agents and is 
indicative of central thermoregulatory inhibition by clonidine. 
 
Carabine et al9, in their study ‘Pre anaesthetic medication with clonidine – a dose 
response study’ on 80 normotensive female patients in which orally administered 
clonidine 0.1mg, 0.2mg, 0.3mg were compared with standard benzodiazepine 
premedicants. The study was conducted in a randomized double blind fashion. 
They found out that clonidine 0.2 mg produced significant reduction in anxiety 
and a better quality of induction of anaesthesia. The decreases in arterial pressure 
and heart rate with clonidine 0.3 mg was significant. In view of the potential for 
undesirable hemodynamic instability persisting into the post-op period, they did 
not recommend the use of clonidine 0.3 mg as a routine premedicant. 
 
Murakami et al10, in their study ‘Oral clonidine reduces the requirement of 
prostaglandin E1 for induced hypotension’ studied the effects of 75 mcg or 150 
mcg clonidine in a randomized double blind study. The study showed that 
preanaesthetic oral clonidine decreased the dose of PGE1 to produce hypotension 
and decrease the blood loss during operation. 
 
Goyagi et al12, in their study ‘Oral clonidine premedication reduces induction 
dose and prolongs awakening time from Propofol – Nitrous oxide anaesthesia’ 
used 39 female ASA I or II, who were randomly allocated to receive 5mcg/kg 
clonidine or placebo 90 minutes before induction of anaesthesia. The induction 
dose of propofol in the clonidine group was less than that of the control group, 
while the awakening time of the clonidine group was longer than that of the 
control group. 
 
Doak et al13, in their study ‘Oral clonidine premedication attenuates the 
hemodynamic effects associated with ketamine induction’ used 40 patients who 
were randomly allocated into clonidine (5mcg/kg), diazepam or placebo groups in 
a double blind fashion and anaesthesia induced with ketamine. They found out that 
increases in heart rate and blood pressure were less in patients given clonidine 
preoperatively than in those who received either diazepam or placebo. 
 
Zaugg et al1, in their study ‘Beneficial effects from beta adrenergic blockade in 
elderly patients undergoing noncardiac surgery’ used 63 patients who were 
randomly assigned to one of the three groups. Group I (no atenolol), Group II (Pre 
and post-op atenolol) & group III (intra-operative atenolol). They showed that 
perioperative beta blockade did not significantly alter the hormonal stress 
response. However the beta blocked patients showed improved hemodynamic 
stability during emergence and post-operatively. It also confers other advantages 
including decreased analgesic requirements and faster recovery from anaesthesia. 
 
 
 CHAPTER VI 
 
AIM 
 
To evaluate the effect of oral atenolol vs. oral clonidine 
premedication for induced hypotension during general anesthesia for patients 
undergoing functional endoscopic sinus surgery based on 
 
1. Intra-operative hemodynamic stability. 
2. Requirement of additional vasodilators. 
3. Peri-operative side effects and complications. 
4. Post-operative hemodynamic stability. 
 
 
 
 
 
 
 
 
 
 
 
 
 CHAPTER VII 
MATERIALS AND METHODS 
 
After getting clearance from the ethics committee, the study was formulated as 
follows. 
 
Study Design 
Randomized experimental double blind study 
Case Definition 
Inclusion Criteria: 
1. Patients belonging to ASA I & II. 
2. Patients between ages 16 to 60. 
3. Patients undergoing FESS procedure. 
Exclusion Criteria: 
1. Hypertensive patients. 
2. H/o Cerebro-vascular accident / Transient ischaemic attack. 
3. Moderate and severe IHD, EF < 40% 
4. Poor respiratory reserve. 
5. Significant hepatic or renal disease. 
6. Contraindication for the use of study drug like bronchospasm, COPD, 
conduction defects and hypersensitivity. 
7. Patients who are not willing to participate in the study. 
Sampling Frame 
Patients undergoing Functional endoscopic sinus surgery at the Upgraded Institute 
of Otorhinolaryngology, Madras Medical College and Hospital, Chennai, India. 
 
Probability Sampling 
Randomization using the lottery method. Sixty lots (twenty in each group) were 
placed to randomize the people who were willing to take part in the study. All the 
patients stand an equal chance of getting into any group with this method. All the 
patients were aware of the study and informed consent obtained. 
 
Sample Size 
Sixty patients, twenty in each of clonidine, atenolol and placebo groups. 
 
Data collection 
A structured assessment schedule was constructed using experts opinion for 
measuring the haemodynamic stability and to monitor the use of intraoperative 
drugs. 
Patient data, vital signs, baseline investigations like haemogram, Hb%, Urea, 
Creatinine, 12 lead EKG and chest X-ray were collected preoperatively. 
Hemodynamic and ventilation parameters like Heart rate, NIBP, Oxygen 
saturation, Lead II EKG were monitored using L&T PlanetTM monitor. FiO2, and 
ventilatory parameters were monitored using the inbuilt ventilator in the Drager 
FabiusTM anaesthesia machine. ETCO2 monitored using CriticareTM monitor 
intraoperatively. 
Continuous lead II EKG monitoring, SpO2, NIBP and heart rate monitoring using 
L&T PlanetTM continued for a minimum of six hours postoperatively in the post 
anaesthesia care unit. 
 
Anaesthesia protocol 
Two 16G IV lines started for the patient on table, standard monitoring 
(ECG, NIBP, SpO2, Temp, ETCO2) were carried out intra-operatively. All the 
patients are preloaded with 500 ml normal saline before induction. 
Nasal packing done with 4% lignocaine with 1:200000 epinephrine. Patient 
preoxygenated for 5 minutes, Anesthesia carried out with Glycopyrrolate 0.2 mg + 
Pethidine 1.0 mg/kg + Xylocard 1.0 mg/kg + Propofol 2.5 mg/kg + Vecuronium 
0.1 mg/kg. Endotracheal intubation done orally with appropriate size ET tube. 
Throat packing done within 1 – 3 minutes post-intubation. 
 Anesthesia maintained with 66% nitrous, 33% oxygen, 0.75% isoflurane, 
with IPPV and vecuronium. 
 
 
Plan: 
 The plan is to maintain the MAP at 70 mm Hg. If MAP is more than the set 
value the following plan of action was taken. 
Step 1:  Increase isoflurane up to 1%. If no response in 10 minutes go 
to step 2. 
Step 2:  To start a titrated NTG infusion. (Each increase in NTG dose 
done with an interval of 5 minutes to allow equilibration of serum therapeutic 
levels.) 
  
Intra-operative hypotension is managed by  
1. IV fluids LR/NS 200 ml 
2. Taper down NTG/volatiles 
3. Ephedrine 3mg i.v. boluses 
 
Intra-op Tachycardia (HR > 150 bpm) controlled using i.v. Metoprolol 1-5 
mg maximum. 
 
Intra-op Bradycardia ( HR < 55 bpm) managed by Glycopyrrolate 0.2 mg 
IM, if not corrected Atropine 0.3 mg IM after 5 min followed by repeated similar 
doses of atropine till desired response is achieved. 
 
 
Intra-op Arrhythmias: 
If haemodynamically stable, continue with the study but with close and increased 
monitoring. 
If unstable, abandon hypotension, volume resuscitate and manage accordingly. 
 
At the end of procedure standard reversal (Neostigmine 50mcg/kg + 
Glycopyrrolate 8mcg/kg) and extubation carried out. 
 
Data Management and Analysis 
 
The variables were entered into SPSS, version 11, statistical software for analysis. 
The descriptive statistics of the variables studied are represented as two-way 
tables. The categorical factors are represented by the number and frequency (%) of 
cases. The continuous variables are represented by measures of central frequency 
(like mean, median & mode) and deviation (say, standard deviation and range). 
The differences in the proportions of are tested for statistical significance using 
non-parametric Chi-square test for variables measured on nominal scale. For 
variables measured on a continuous scale, one-way analysis of variance (ANOVA) 
is employed to elicit the statistical significance of three variables taken together. 
When testing for two groups, Student “t” test is used to test for statistical 
significance in the differences of the two means. Line graphs were used to 
illustrate the hemodynamic monitoring at different time points. Box plot graphs 
were employed to depict the distribution of other factors in the three groups. 
 
 
 
 
 
CHAPTER VIII 
 
METHOD DESIGN 
 
 
Study Population 
(Patients at ENT ward, MMC, GH, who are enrolled in the study) 
 
 
 
Informed Consent 
 
 
 
Pre-operative evaluation 
 
 
Randomization 
[Placebo(20) Clonidine(20) Atenolol(20)] 
 
 
 
FESS Procedure 
 
 
 
Monitoring and Evaluation 
Data Collection 
Patient Assessment 
 
 
Data entry and management 
 
 
Data Analysis 
 
 
 
Study outcome 
  
 
Intervention 
A non labeled multi vitamin tablet was given PO to the patients in the placebo 
group at 7.00 pm the day before surgery and also 2 hours before surgery. 
A non labeled clonidine tablet was given PO to the patients in the clonidine group 
in the dose of 2mcg/kg at 7.00 pm the day before surgery and 4mcg/kg 2 hours 
before surgery. 
A non labeled atenolol 25 mg tablet was given PO to the patients in atenolol group 
at 7.00 pm the day before surgery and also 2 hours before surgery. 
 
Blinding 
The study was a double blind study where in the investigator (Anaesthetist) and 
the study patients were not aware of the interventions done. 
 
Duration of the study 
The study was completed in a duration of four months. 
 
 
 
 
  
Measurement of study variables 
The study instrument measured the following parameters 
1. Heart rate 
2. Systolic blood pressure 
3. Diastolic blood pressure 
4. Mean arterial pressure 
5. Requirement of Isoflurane and Nitroglycerin 
6. Preoperative and postoperative sedation scores 
7. Postoperative shivering 
8. Intraoperative problems (Hypotension, Hypertension, Arrhythmias, 
Tachycardia, Bradycardia, Ischaemia) 
9. Duration of surgery 
10. Operating field 
11. Post operative analgesic request time 
12. Post anaesthesia discharge criteria 
 
Intra-op drug scores: 
ISOFLURANE  VOL%    SCORE 
    0 – 0.75%   0 
    0.75%    1 
    1.0%    2 
 
NITROGLYCERIN  DOSE    SCORE 
    0.3mcg kg-1min-1  1 
    0.6mcg kg-1min-1  2 
    1.0mcg kg-1min-1  3 
    1.5mcg kg-1min-1  4 
    2.0mcg kg-1min-1  5 
    2.5mcg kg-1min-1  6 
    3.0mcg kg-1min-1  7 
    4.0 mcg kg-1min-1  8 
    5.0 mcg kg-1min-1  9 
 
METOPROLOL  DOSE    SCORE 
    < 2mg    1 
    2-4 mg   2 
    >4mg    3 
 
Sedation score: 
 (Based on Ramsay sedation scale) 
 
Anxious, Agitated, Restless.       1 
Co-operative, Oriented, Tranquil.       2 
Asleep, Brisk response to light glabellar tap / loud auditory stimulus.  3 
Asleep, sluggish response to brisk glabellar tap / loud auditory stimulus. 4 
No response to above.        5 
No response to pain.         6 
 
 
POST ANAESTHESIA DISCHARGE SCORING SYSTEM 
 
Score 0 1 2 
Vital signs >40% of 
preoperative 
baseline 
20 – 40% of 
preoperative 
baseline 
Within 20% of 
preoperative 
baseline 
Activity Unable to 
ambulate 
Dyspnoeic, 
requires assistance 
Steady gait, no 
dizziness or pre-op 
level 
Nausea & 
Vomiting 
 
Continues after 
repeated treatment 
Moderate, treated 
with IM 
medications 
Minimal, treated 
with PO 
medications 
Pain (Acceptable 
to the patient; 
controlled with 
PO meds) 
 
- No Yes 
Surgical bleeding Minimal, no 
dressing change 
required 
Moderate, up to 
two dressing 
changes 
Severe, more than 
three dressing 
changes 
 
 A score of 9 or more is required to meet the fitness for discharge. 
 
 
 
 
 
 
CHAPTER IX 
OBSERVATION AND RESULTS 
 
DEMOGRAPHIC DATA 
TABLE I 
 
Age distribution$ 
Age PLACEBO 
(P) 
CLONIDINE 
(C) 
ATENOLOL 
(A) p-value 
No. of cases 
Mean 
S.D. 
Median 
Mode 
Range 
20 
27.0 
7.36 
25 
22 
19-48 
20 
25.9 
7.66 
24 
19 
16-43 
20 
23.5 
4.71 
22 
10 
17-35 
 
 
0.25 
Stat. Significance 
 C vs. P 
 A vs. P 
 C vs. A 
p-value 
0.66 
0.08 
0.23 
 
$ Not statistically significant 
 
The mean age between the comparison groups are almost similar. The minimum 
age taken for the study is 16 and the maximum is 48. 
 
TABLE II 
 
Sex distribution$ 
 
PLACEBO 
(P) 
CLONIDINE 
(C) 
ATENOLOL 
(A) 
 
No. % No. % No. % 
p-value 
 
MALE 
FEMALE 
 
14 
6 
70.0
30.0
13
7
65.0
35.0
11
9
 
55.0 
45.0 
 
0.61 
Stat. Significance 
 C vs. P 
 A vs. P 
 C vs. A 
p-value 
0.52 
0.33 
0.74 
 
$ Not statistically significant 
 
A male preponderance is forthcoming in all the study groups. However, the 
distribution of sex among the groups is not statistically significant. 
 
TABLE III 
 
Weight distribution 
Weight PLACEBO 
(P) 
CLONIDINE 
(C) 
ATENOLOL 
(A) p-value 
No. of cases 
Mean 
S.D. 
Median 
Mode 
Range 
20 
53.9 
9.47 
50 
50 
40-80 
20 
55.4 
8.65 
50 
50 
45-75 
20 
51.3 
9.44 
50 
40 
40-70 
 
 
0.36 
Stat. Significance 
 C vs. P 
 A vs. P 
 C vs. A 
p-value 
0.59 
0.39 
0.16 
 
 
 
The mean distribution of cases by weight was observed to be not statistically 
significant between Group 1 and Group 2 as well as between the groups and 
control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE IV 
 
Intra operative Hemodynamic parameters 
 
Parameter 
 
Placebo Group Clonidine group p Value 
Heart Rate 
 
Before Induction 99.1 ± 17 78.1 ± 20 0.001* 
After Induction 99.3 ± 17.1 75.4 ± 12.7 0.000* 
After Intubation 104.9 ± 9.1 78.2 ± 2.34 0.001* 
Average Intra-op 84.7 ± 4 72.5 ± 2.05 0.000* 
Immediate Post-op 103.3 ± 6.1 77.1 ± 2.6 0.003* 
Systolic Blood Pressure 
 
Before Induction 131.6 ± 16.8 106.4 ± 14.3 0.000* 
After Induction 112.1 ± 17 96.9 ± 13.9 0.004* 
After Intubation 117.6 ± 19.7 95.8 ± 5.7 0.078 
Average Intra-op 91.5 ± 3.59 90 ± 4.69 0.482 
Immediate Post-op 125.7 ± 8.47 108.8 ± 2.81 0.030* 
Diastolic Blood Pressure 
 
Before Induction 89.9 ± 11.9 72.4 ± 11.5 0.000* 
After Induction 76.6 ± 12.3 62.7 ± 13.2 0.001* 
After Intubation 80.2 ± 13.3 64 ± 4 0.059 
Average Intra-op 61.5 ± 2.7 60 ± 2.67 0.293 
Immediate Post-op 86.5 ± 5.61 75.7 ± 3.3 0.046* 
Mean Arterial Pressure 
 
Before Induction 102.4 ± 15 83.6 ± 11.2 0.000* 
After Induction 84.9 ± 22.7 74.5 ± 13.2 0.085 
After Intubation 92.5 ± 15.4 74.4 ± 4.6 0.066 
Average Intra-op 71.4 ± 2.93 70 ± 3.37 0.382 
Immediate Post-op 99.2 ± 6.8 86.7 ± 3.1 0.044* 
 
 
 
 
 
 
 
 
 
 
 
TABLE V 
 
Intra operative Hemodynamic parameters 
 
Parameter 
 
Placebo Group Atenolol Group p Value 
Heart Rate 
 
Before Induction 99.1 ± 17 67.2 ± 8.23 0.000* 
After Induction 99.3 ± 17.1 67 ± 9.95 0.000* 
After Intubation 104.9 ± 9.1 72.2 ± 2.47 0.000* 
Average Intra-op 84.7 ± 4 66.6 ± 1.47 0.000* 
Immediate Post-op 103.3 ± 6.1 68.7 ± 5.13 0.002* 
Systolic Blood Pressure 
 
Before Induction 131.6 ± 16.8 111.7 ± 9.09 0.000* 
After Induction 112.1 ± 17 95.1 ± 7.22 0.000* 
After Intubation 117.6 ± 19.7 105.1 ± 10.48 0.30 
Average Intra-op 91.5 ± 3.59 89.1 ± 1.28 0.09 
Immediate Post-op 125.7 ± 8.47 117.5 ± 6.69 0.259 
Diastolic Blood Pressure 
 
Before Induction 89.9 ± 11.9 79.1 ± 7.58 0.001* 
After Induction 76.6 ± 12.3 64.3 ± 7.52 0.001* 
After Intubation 80.2 ± 13.3 73 ± 7.62 0.384 
Average Intra-op 61.5 ± 2.7 59.9 ± 1.91 0.191 
Immediate Post-op 86.5 ± 5.61 81.7 ± 7.17 0.406 
Mean Arterial Pressure 
 
Before Induction 102.4 ± 15 89.8 ± 7.96 0.002* 
After Induction 84.9 ± 22.7 74.4 ± 6.91 0.054 
After Intubation 92.5 ± 15.4 83.5 ± 8.26 0.343 
Average Intra-op 71.4 ± 2.93 68.9 ± 1.49 0.046 
Immediate Post-op 99.2 ± 6.8 93.6 ± 6.64 0.364 
 
 
 
 
 
 
 
 
 
 
 
TABLE VI 
 
Intra operative Hemodynamic parameters 
 
Parameter 
 
Clonidine group Atenolol Group p Value 
Heart Rate 
 
Before Induction 78.1 ± 20 67.2 ± 8.23 0.035* 
After Induction 75.4 ± 12.7 67 ± 9.95 0.026* 
After Intubation 78.2 ± 2.34 72.2 ± 2.47 0.012* 
Average Intra-op 72.5 ± 2.05 66.6 ± 1.47 0.000* 
Immediate Post-op 77.1 ± 2.6 68.7 ± 5.13 0.065 
Systolic Blood Pressure 
 
Before Induction 106.4 ± 14.3 111.7 ± 9.09 0.172 
After Induction 96.9 ± 13.9 95.1 ± 7.22 0.611 
After Intubation 95.8 ± 5.7 105.1 ± 10.48 0.172 
Average Intra-op 90 ± 4.69 89.1 ± 1.28 0.608 
Immediate Post-op 108.8 ± 2.81 117.5 ± 6.69 0.106 
Diastolic Blood Pressure 
 
Before Induction 72.4 ± 11.5 79.1 ± 7.58 0.037* 
After Induction 62.7 ± 13.2 64.3 ± 7.52 0.632 
After Intubation 64 ± 4 73 ± 7.62 0.083 
Average Intra-op 60 ± 2.67 59.9 ± 1.91 0.9 
Immediate Post-op 75.7 ± 3.3 81.7 ± 7.17 0.262 
Mean Arterial Pressure 
 
Before Induction 83.6 ± 11.2 89.8 ± 7.96 0.053 
After Induction 74.5 ± 13.2 74.4 ± 6.91 0.438 
After Intubation 74.4 ± 4.6 83.5 ± 8.26 0.103 
Average Intra-op 70 ± 3.37 68.9 ± 1.49 0.4 
Immediate Post-op 86.7 ± 3.1 93.6 ± 6.64 0.179 
 
 
 
 
 
 
 
 
 
 
• There is a statistically significant difference in the mean heart rate 
measured during the five intraoperative events (presented in the tables 4, 5 
and 6) among the placebo and the treatment groups. There is a significant 
reduction in heart rate in the atenolol group when compared to the clonidine 
group. 
• There is a statistically significant difference in systolic BP between the 
placebo group and the treatment groups during the five events. However 
there is no statistically significant difference between the clonidine and the 
atenolol group. 
• Diastolic BP, when measured before and after induction had a statistically 
significant difference among the placebo and the treatment groups. 
Between the clonidine and atenolol groups there is a significant difference 
only before induction. All other events were not statistically significant. 
• The mean arterial pressure before induction is statistically significant 
between the placebo group and the treatment group. Here again between the 
clonidine and the atenolol group no statistical significance is demonstrated. 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE VII 
 
Intraoperative requirement of Isoflurane 
 
 
 
High requirement Moderate 
requirement 
Low requirement 
Placebo group  60% 40% 0 
Clonidine group  0 10% 90% 
Atenolol group  0 5% 95% 
 
 
Interpretation of Isoflurane requirements 
• High – Patients requiring 1% for 15 minutes or more 
• Moderate – Patients requiring 0.75% or more for more than 15 minutes 
• Low – Patients who require less than 0.75% isoflurane 
  
Majority cases in the treatment group have a low requirement of isoflurane 
intraoperatively which is in contrast to the majority of cases in the placebo group 
which has a high requirement of isoflurane intraoperatively. None of the cases in 
either of the treatment groups had a high requirement of isoflurane 
intraoperatively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE VIII 
 
Intraoperative requirement of Nitroglycerin 
Placebo group  60% 
Clonidine group  0 
Atenolol group  0 
 
 
Majority of cases in the control group required nitroglycerin intraoperatively. 
None of the cases in either of the treatment groups required nitroglycerin 
intraoperatively. 
 
TABLE IX 
INTRA-OPERATIVE ADVERSE EVENTS 
 
PLACEBO CLONIDINE ATENOLOL Intra operative 
Problems No. % No. % No. % p-value 
ARRYTHIMIA 
   Yes 
   No 
 
0 
20 
0.0
100.0
0
20
0.0
100.0
0
20
 
0.0 
100.0 
 
- 
HYPOTENSION** 
   Yes 
    No 
 
8 
12 
40.0
60.0
5
15
25.0
75.0
1
19
 
5.0 
95.0 
 
0.03* 
HYPERTENSION 
    Yes 
    No 
 
3 
17 
15.0
85.0
2
18
10.0
90.0
0
20
 
0.0 
100.0 
 
1.00 
TACHYCARDIA 
    Yes 
    No 
 
0 
20 
0.0
100.0
0
20
0.0
100.0
0
20
 
0.0 
100.0 
 
- 
BRADYCARDIA 
    Yes 
    No 
 
1 
19 
5.0
95.0
1
19
5.0
95.0
1
19
 
5.0 
95.0 
 
0.60 
ISCHAEMIA 
    Yes 
    No 
 
0 
20 
0.0
100.0
0
20
0.0
100.0
0
20
 
0.0 
100.0 
 
- 
 
 
Majority of the cases in the placebo group tended to develop adverse events, 
Hypotension was the commonest recorded adverse event. 
 In the atenolol group, majority of cases did not develop any haemodynamic 
instability except one, who developed hypotension. 
 In the clonidine group five cases developed hypotension and two developed 
hypertension.  
The incidence of bradycardia was one case each in placebo and clonidine group. 
Intra operative problems such as tachycardia, arrhythmias and ischaemia are 
not seen in any of the groups 
 
 
TABLE X 
EVALUATION OF OPERATING CONDITIONS BY SURGEON 
 
 
Operating Field 
 
Placebo Group Clonidine Group Atenolol Group Total 
 Excellent 9 11 7 27 
  Good 11 9 13 33 
Total   20 20 20 60 
 
 
 
TABLE X (Cont’d) 
Chi square tests 
 
  Value Degree of freedom p Value 
Pearson Chi-Square 1.616 2 .446 
Likelihood Ratio 1.628 2 .443 
N of Valid Cases 60   
 
 
 
 
 
 
 
 
 
 
TABLE XI 
EFFECT OF STUDY DRUGS ON DURATION OF SURGERY 
 
Duration of surgery PLACEBO 
(P) 
CLONIDINE 
(C) 
ATENOLOL 
(A) p-value 
No. of cases 
Mean 
S.D. 
Median 
Mode 
Range 
20 
70.3 
20.49 
65 
55 
45-120 
20 
59.0 
22.34 
57.5 
40 
25-110 
20 
70.5 
15.72 
67.5 
65 
45-115 
 
 
0.31 
Stat. Significance 
 C vs. P 
 A vs. P 
 C vs. A 
p-value 
0.11 
0.97 
0.07 
 
$ Not statistically significant 
 
 
• All the groups provided similar operating field conditions. They provided 
either excellent or good operating field conditions, with no statistically 
significant difference among them. 
• There is no statistical significant difference in the duration of surgery 
between the three groups. 
 
TABLE XII 
POST-OPERATIVE SHIVERING 
 
   Placebo Group Clonidine group Atenolol Group Total 
NO 13 20 14 47 Post operative 
shivering  
YES 7  6 13 
Total  20 20 20 60 
 
TABLE XII (Cont’d) 
 
Chi square tests 
 
  Value Degree of freedom p Value 
Pearson Chi-Square 8.445 2 .015 
Likelihood Ratio 12.386 2 .002 
N of Valid Cases 60   
 
• None of the patients in the clonidine group developed postoperative 
shivering. 
• 30% and 35% of the patients developed postoperative shivering in the 
atenolol and the placebo groups respectively. 
• There is a statistical significance between the clonidine group and the other 
two groups. 
 
TABLE XIII 
POST-OP SEDATION SCORE 
 
 
TABLE XIII (Cont’d) 
 
Chi Square Tests 
 
  Value Degree of freedom p value 
Pearson Chi-Square 10.526 6 .104 
Likelihood Ratio 11.863 6 .065 
Linear-by-Linear Association .164 1 .685 
N of Valid Cases 60   
 
Majority of cases in all the three groups had a postoperative sedation score of 4. 
There is no statistical significant difference among groups. 
 
 
 
 
  Placebo Group Clonidine Group Atenolol Group Total 
Post-op Sedation Score 2 6 3 1 10 
  3 2 8 9 19 
  4 11 9 10 30 
  5 1   1 
Total  20 20 20 60 
TABLE XIV 
TIME FOR ANALGESIA REQUEST 
 
Analgesic request 
(hours after 
extubation) 
PLACEBO 
(P) 
CLONIDINE 
(C) 
ATENOLOL 
(A) p-value 
No. of cases 
Mean 
S.D. 
Median 
Mode 
Range 
20 
0.2 
0.37 
0 
0 
0-1 
20 
6.4 
1.54 
7 
7 
2-8 
20 
0.4 
0.81 
0 
0 
0-3 
 
 
<0.001* 
Stat. Significance 
 C vs. P 
 A vs. P 
 C vs. A 
p-value 
<0.001* 
0.32 
<0.001* 
 
* Statistically significant 
 
The median hours after extubation for request of rescue analgesic by the patient 
was 7 in clonidine group compared to <1 hour among atenolol group and placebo 
group. The mean distribution of cases by analgesic request (in hours after 
extubation) was observed to be statistically significant between clonidine group 
and atenolol group as well as between the clonidine group and placebo group. 
However, it was not statistically significant between atenolol group and placebo 
group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE XV 
PADSS – 6 HOURS POST-OP 
  
PLACEBO 
(P) 
CLONIDINE 
(C) 
ATENOLOL 
(A) 
PADSS-6 pm on 
the day of surgery 
No. % No. % No. % 
p-value 
 
6 
7 
8 
9 
 
0 
5 
13 
2 
0.0
25.0
65.0
10.0
3
17
0
0
15.0
85.0
0.0
0.0
0
3
17
0
 
0.0 
15.0 
85.0 
0.0 
 
 
<0.001* 
Stat. Significance 
 C vs. P 
 A vs. P 
 C vs. A 
p-value 
<0.001* 
0.22 
<0.001* 
 
* Statistically significant 
 
 
 
PADSS – 18 HOURS POST-OP 
 
PLACEBO 
(P) 
CLONIDINE 
(C) 
ATENOLOL 
(A) 
PADSS-6 am 
 1st POD 
No. % No. % No. % 
p-value 
 
7 
8 
9 
10 
 
1 
0 
12 
7 
5.0
0.0
60.0
35.0
2
0
18
0
10.0
0.0
90.0
0.0
0
1
14
5
 
0.0 
5.0 
70.0 
25.0 
 
 
0.07 
Stat. Significance 
 C vs. P 
 A vs. P 
 C vs. A 
p-value 
0.01* 
0.48 
0.04* 
 
* Statistically significant 
 
There is a statistically significant difference in PADSS among the three 
groups with only 10% of the cases in the placebo group meeting the discharge 
criteria on the same day of surgery. Majority of the patients were fit to be 
discharged the next day morning with no statistical significance among the three 
groups. 
 
 
 
 
CHAPTER X 
 
DISCUSSION 
 
 
Premedication is not only for sedation and anxiolysis, but also to 
enhance the quality of induction, maintenance and recovery from anaesthesia. The 
primary goal of an anaesthetist in FESS procedure is to provide better surgical 
access, a bloodless operating field, conduct of balanced anaesthesia and prompt 
recovery. To provide a bloodless operating field, induced hypotension is a clear 
answer in addition to proper positioning (150 reverse trendelenberg position) to 
promote venous drainage. In order to achieve a better operating field, the surgeon 
on his part packs the nasal cavity with vasoconstrictor and infiltrates the field with 
adrenaline before incision. Most surgeons use concentrations of more than 
1:200000 for this purpose. This infiltration of adrenaline poses a challenge to the 
anaesthetist in performing induced hypotension along with the problem of 
managing intubation responses. The patient’s anxiety compounds the problem. 
In order to manage all these problems, adequate and appropriate 
premedication plays an important role in this regard. 
 This study has compared the efficacy of oral clonidine and 
oral atenolol to achieve these desired conditions. As per this study the three groups 
did not demonstrate any statistical significance in demographic distribution. 
 The resting heart rate and blood pressure were significantly reduced 
in the treatment groups compared to the placebo group, with atenolol faring better 
than clonidine.  
The pre-op sedation score did not vary between the three groups, but 
the clinical significance was demonstrated with two patients in the placebo group 
presenting with restlessness before surgery.  
Intubation responses were blunted among the treatment groups when 
compared with the placebo groups, once again atenolol doing better.  
The results of the study of Mikawa et al8, that premedication with 
oral clonidine attenuates intubation response concurs with the findings of the 
study. 
Patients in the treatment group mostly had a low requirement for 
isoflurane, with  5-10% of the patients requiring isoflurane of 0.75% or more for 
more than 15 minutes. In the placebo group, 40% of the patients required more 
than 0.75% isoflurane for more than 15 minutes, while 60% of the cases required 
1% isoflurane for more than 15 minutes. In the clonidine group 10% of the 
patients had a moderate requirement of isoflurane in comparison with only 5% in 
the atenolol group. The atenolol group fared better than clonidine group in the 
intra-op requirements for isoflurane. 
 There was no significant difference in the hemodynamic parameters 
intra-operatively among the three groups. 
The results of the study of Maroof et al7, that premedicating with 
4mcg/kg of clonidine for hypotensive anaesthesia resulted in better hemodynamic 
stability have concurred with the findings of the study. 
The findings of Zaugg et al1, in their study that premedication with 
atenolol confer advantages of decreased analgesic requirements and faster 
recovery did not correlate with the findings of the study.  
 None of the patients in the treatment group required NTG intra-
operatively.  
Intra-operative problems like arrhythmia, tachycardia and ischaemia 
were never encountered among the three groups. 
 Hypotension was the most common intra-operative problem 
encountered, with 8 (40%) and 5(25%) patients in the placebo and clonidine group 
respectively, demonstrating statistical significance. Only one patient had 
hypotension in the atenolol group. 
 Hypertension was encountered in three patients in the placebo 
group, two patients in clonidine group and none in atenolol group. The 
hypertension that occurred in the clonidine group was possibly in response to 
adrenaline infiltration. Failure to standardize the concentration of adrenaline used 
for infiltration has been a limitation in this study to merit any further comment. 
 One patient in each group experienced bradycardia which was 
promptly treated with intravenous atropine. The atenolol group encountered the 
least number of intra-operative problems. 
 Excellent to good operating field conditions were provided with all 
the three groups. No significant difference in the duration of surgery was produced 
between the treatment and placebo groups. Failure to standardize the operating 
surgeon limits further comment. 
There was a statistically significant difference with extubation 
responses between the placebo group and the clonidine group with no statistically 
significant difference between the atenolol and the placebo group. 
None of the patients experienced post operative shivering in the 
clonidine group, whereas 30 – 35% patients suffered post-op shivering in the other 
two groups.  
The results of the study of Buggy et al4, that clonidine at induction 
reduces shivering after GA, supports our evidence of decreased incidence of 
shivering in the clonidine group. 
The post-op sedation scores did not significantly vary among the 
three groups with a majority of the patients in the three groups having a sedation 
score of 4. 
The results in the study of Bellaiche et al6, that clonidine does not 
delay recovery from anaesthesia supports our evidence of statistical insignificance 
in post-op sedation score among the three groups. 
 
 
 
The results of the study by Goyagi et al12, that awakening time of 
patients premedicated with clonidine was longer than the control group contrasted 
with the findings of the study. However the dose of clonidine used by Goyagi was 
higher than that was used in the study, which necessitates further analysis in this 
regard. 
 Patients in the clonidine group did not require post-op analgesic 
supplement for a mean duration of 6.4 hours after surgery in comparison with 0.2 
and 0.4 hours in placebo and atenolol groups respectively. Thus clonidine has 
offered better post-op analgesia in comparison with other groups.  
Only 10% of the patients in placebo group met the discharge criteria 
at 6.00 pm on the day of surgery, none meeting the criteria in the treatment groups. 
While 90 – 95% of the patients in the three groups met the discharge criteria at 
6.00 am on the next day of surgery. Patients in clonidine group scored lower in 
PADSS when compared to the other two groups. The findings in this study seem 
to suggest that FESS procedure is not ideal for being performed as a daycare 
surgery. The fact that the patients in clonidine group landed up with poor PADSS 
score precludes the use of oral clonidine as premedicant when daycare anaesthesia 
is contemplated.  
 
 
 
 
 
 
CHAPTER XI 
 
SUMMARY 
 
 
 
This prospective randomized study aimed to analyze the effect of 
atenolol and clonidine premedication on the peri-operative characteristics of 
patients undergoing FESS procedure under GA and induced hypotensive 
anaesthetic technique. 
The important conclusions from this study include 
1. Clonidine and atenolol premedication produces predictable and superior 
hemodynamics during peri-operative period, with atenolol being superior to 
clonidine. 
2. Clonidine and atenolol premedication decreases the intra-operative 
requirement of vasodilators like NTG. 
3. Clonidine and atenolol premedication decreases the requirement of 
inhalational anaesthetics like isoflurane to maintain hemodynamic control. 
4. Clonidine premedication produces increased incidences of undesirable 
alterations in BP, which extended into the early post-op period, but could 
be easily treated. 
5. Clonidine produces better sedation and anxiolysis pre-op and reduces the 
requirement of post-op analgesia as noted by delayed TAR times. 
6. Clonidine reduces the incidence of post-anaesthetic shivering. 
7. Atenolol produces lesser perturbations in HR and BP in response to 
intubation. 
8. Atenolol produces very minimal hemodynamically adverse events during 
the perioperative period. 
9. Lack of standardization of vasoconstrictors infiltrated by the surgeon 
maybe a limiting factor in the study. 
10. Clonidine premedication produces poorer PADSS score reflecting inability 
to meet discharge criteria of daycare surgery. 
11. FESS procedures seem to be inappropriate for consideration for daycare 
surgery with the most common morbidity factors being headache and pain. 
12. Balanced anaesthesia technique with meticulous attention to patients needs 
is the single most important factor in production of controlled hypotension 
during surgery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER XII 
 
 
CONCLUSION 
 
 
 Clonidine and Atenolol premedication provides superior and predictable 
perioperative hemodynamic control, reduces the requirement of hypotensive 
agents and produces acceptable recovery characteristics. 
The lesser incidence of complications recorded with Atenolol gives it a more 
favorable profile when compared to Clonidine. 
Clonidine or Atenolol premedication can form an important and desirable part of 
hypotensive anaesthesia for surgical procedures like FESS. 
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COMPARATIVE STUDY OF ORAL ATENOLOLVERSUS ORAL 
CLONIDINE FOR HYPOTENSIVE ANESTHESIA FOR PATIENTS 
UNDERGOING FUNCTIONAL ENDOSCOPIC SINUS SURGERY 
UNDER GENERAL ANESTHESIA – PROFORMA. 
 
 
 
NAME:     AGE:    SEX: 
 
WEIGHT: 
 
IP NUMBER: 
 
DIAGNOSIS:       SURGEON: 
 
PROCEDURE:      ANESTHETIST: 
 
RANDOM NUMBER: 
 
PRE-OP SEDATION SCORE*: 
 
PRE-OP EVALUATION: 
 
Pulse:   BP:  SpO2:   ECG: 
 
PFT:        ECHO: 
 
BREATH HOLDING TEST:     Hb%: 
 
LFT:        Renal parameters: 
 
 
 
Intra-op Drugs Dosage Total dose given 
Narcotics Pethidine   
Induction agent Propofol   
Muscle relaxant Vecuronium   
Others Xylocard   
 
 
 
HEMODYNAMICS MONITORING 
 
Events HR SBP DBP MAP SpO2 ETCO2 Rhythm U/O Iso NTG Others
Pre-
induction 
           
After 
induction 
           
After 
intubation 
           
1’            
2’            
3’            
4’            
5’            
10’            
15’            
20’            
25’            
30’            
35’            
40’            
45’            
50’            
55’            
60’            
65’            
70’            
75’            
80’            
85’            
90’            
95’            
100’            
105’            
110’            
115’            
120’            
125’            
130’            
135’            
140’            
145’            
150’            
155’            
160’            
Events HR SBP DBP MAP SpO2 ETCO2 Rhythm U/O Iso NTG Others
165’            
170’            
175’            
180’            
185’            
190’            
195’            
200’            
205’            
210’            
215’            
220’            
225’            
230’            
After 
neostigmine 
           
2’            
4’            
10’            
After 
extubation 
           
2’            
5’            
15’            
30’            
 
INTRA-OPERATIVE PROBLEMS: 
 
Hypertension (20% above baseline) Yes/No Episodes: 
Hypotension (BP below set value – MAP 60 
mmHg) 
Yes/No Episodes: 
Arrhythmias Yes/No Episodes: 
Bradycardia (HR < 50 bpm) Yes/No Episodes: 
Tachycardia (HR < 150 bpm) Yes/No Episodes: 
Ischaemic changes Yes/No Episodes: 
 
SURGEONS ASSESMENT OF FIELD: 
 
Excellent  Good   Fair   Poor 
 
Duration of surgery: 
 
Time between reversal of NM blockade and extubation: 
 
Surgeon’s Comments (if any): 
 
 
POST-OPERATIVE FACTORS: 
 
Delayed recovery Yes/No 
Shivering Yes/No 
Time of 1st analgesic request  
Hemodynamic changes Yes/No 
Vomiting Yes/No 
 
Post-op sedation score: 
 
INTRA-OP DRUG SCORES: 
 
ISOFLURANE -   VOL%    SCORE 
    0 – 0.75%   0 
    0.75%    1 
    1.0%    2 
 
NITROGLYCERIN  DOSE    SCORE 
    0.3mcg kg-1min-1  1 
    0.6mcg kg-1min-1  2 
    1.0mcg kg-1min-1  3 
    1.5mcg kg-1min-1  4 
    2.0mcg kg-1min-1  5 
    2.5mcg kg-1min-1  6 
    3.0mcg kg-1min-1  7 
    4.0 mcg kg-1min-1  8 
    5.0 mcg kg-1min-1  9 
 
METOPROLOL  DOSE    SCORE 
    < 2mg    1 
    2-4 mg    2 
    >4mg    3 
 
 
* SEDATION SCORES: 
 (Based on Ramsay sedation scale) 
 
Anxious, Agitated, Restless.        1 
Co-operative, Oriented, Tranquil.       2 
Asleep, Brisk response to light glabellar tap / loud auditory stimulus.  3 
Asleep, sluggish response to brisk glabellar tap / loud auditory stimulus.  4 
No response to above.         5 
No response to pain.         6 
 
 
Post anaesthesia discharge scoring system (PADSS) 
 
Vital signs (BP & Pulse) 
2 = Within 20% of preoperative baseline 
1 = 20 – 40% of preoperative baseline 
0 = >40% of preoperative baseline 
 
Activity 
2 = Steady gait, no dizziness or pre-op level 
1 = Dyspnoeic, requires assistance 
0 = Unable to ambulate 
 
Nausea & Vomiting 
2 = Minimal, treated with PO medications 
1 = Moderate, treated with IM medications 
0 = Continues after repeated treatment 
 
Pain 
Acceptable to the patient; controlled with PO meds 
2 = Yes 
1 = No 
 
Surgical bleeding 
2 = Minimal, no dressing change required 
1 = Moderate, up to two dressing changes 
0 = Severe, more than three dressing changes 
 
Patient Score 
6.00 pm on the day of surgery  
6.00 am 1st POD  
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NAME AGE SEX WEIGHT IP NUMBER PRE OP SEDATION SCORE
MAHESWARI 22 F 40 791910 2
RASHEEDA 31 F 40 785915 2
MURALINATHAN 19 M 60 785816 2
KOKILA 25 F 40 782946 2
RAMYA 17 F 50 783254 2
VIJAYAN 19 M 45 785092 2
PRAKASH 22 M 50 785559 2
RAJA 35 M 65 787789 2
MURUGANANTHAM 24 M 60 795603 2
PREMA 20 F 50 795717 2
PICHANDI 30 M 55 795796 2
ANANDAN 22 M 60 795813 2
DURAI 19 M 45 795836 2
RAMAKRISHNAN 27 M 70 795884 2
VIJAYA 23 F 60 795902 2
THANGADURAI 25 M 60 795917 2
SEETHAMMA 28 F 45 796008 2
JUSTIN 20 M 40 796213 2
PONNU 21 F 40 796227 2
FATHIMA 20 F 50 796309 2
HR SBP DBP MAP SOFLURAN NTG HR SBP DBP
92 113 80 91 0 0 91 105 72
71 104 76 85 0 0 72 88 52
68 118 76 90 0 0 80 101 68
73 113 76 88 0 0 81 82 57
64 100 70 80 0 0 84 93 58
73 103 73 83 0 0 69 102 72
67 102 68 77 0 0 61 94 55
62 112 79 90 0 0 59 102 72
69 128 96 107 0 0 60 99 67
61 107 78 88 0 0 60 94 55
55 117 81 93 0 0 54 92 69
59 110 72 85 0 0 56 81 48
57 127 86 100 0 0 61 102 67
60 96 74 81 0 0 62 99 67
63 105 77 86 0 0 64 90 63
67 122 91 101 0 0 65 105 70
72 118 78 91 0 0 70 96 73
77 105 77 86 0 0 63 100 70
69 112 79 90 0 0 67 91 68
66 123 95 104 0 0 61 86 64
PRE INDUCTION AFTER IN
MAP SOFLURAN NTG HR SBP DBP MAP SOFLURAN NTG
83 0 0 89 130 96 107 0 0
64 0 0 99 149 102 118 1 0
79 0 0 95 127 87 100 0 0
65 0 0 97 96 82 87 1 0
70 0 0 86 97 68 78 1 0
82 0 0 72 123 95 104 1 0
68 0 0 67 132 98 109 1 0
82 0 0 64 127 86 100 1 0
77 0 0 63 101 77 85 1 0
68 0 0 69 105 77 86 1 0
77 0 0 67 128 89 102 1 0
59 0 0 71 118 78 91 1 0
76 0 0 77 116 78 91 1 0
77 0 0 69 118 78 91 1 0
72 0 0 66 107 71 83 1 0
82 0 0 72 106 75 85 1 0
80 0 0 81 132 88 103 1 0
80 0 0 66 112 79 90 1 0
76 0 0 68 124 90 101 1 0
71 0 0 62 124 75 81 1 0
DUCTION AFTER INTUBATION
HR SBP DBP MAP SOFLURAN NTG HR SBP DBP
79 101 67 78 2 0 79 101 67
94 102 68 79 1 0 72 98 66
98 124 82 96 1 0 91 96 64
101 122 96 105 1 0 89 97 71
86 98 69 79 1 0 84 97 69
74 113 72 86 1 0 70 96 73
65 109 77 88 1 0 64 106 76
63 100 66 77 1 0 66 107 78
61 100 70 80 1 0 62 97 69
67 102 69 80 1 0 61 102 72
72 109 78 88 1 0 70 102 72
74 100 73 82 1 0 72 103 73
64 109 60 76 1 0 71 107 72
69 110 77 88 1 0 68 103 73
64 124 75 81 1 0 63 107 72
69 95 68 79 1 0 65 104 63
72 109 78 88 1 0 70 107 72
70 98 71 80 1 0 66 98 73
70 108 71 83 1 0 69 101 72
59 101 68 79 1 0 54 102 68
1' 2
MAP SOFLURAN NTG HR SBP DBP MAP SOFLURAN NTG
78 2 0 83 95 63 74 2 0
77 1 0 79 96 63 74 1 0
75 1 0 85 94 63 73 1 0
80 2 0 81 85 56 66 2 0
78 2 0 84 91 65 74 2 0
80 2 0 78 94 60 71 2 0
86 2 0 62 91 69 76 2 0
88 2 0 59 97 58 71 2 0
78 2 0 65 101 77 85 2 0
82 2 0 67 98 74 82 2 0
82 2 0 76 95 56 69 2 0
83 2 0 76 90 68 75 2 0
84 2 0 58 90 68 75 2 0
83 2 0 63 91 62 72 2 0
84 2 0 61 89 60 70 2 0
81 2 0 67 91 67 75 2 0
84 2 0 74 91 68 76 2 0
81 2 0 62 98 71 80 2 0
82 2 0 64 90 64 73 2 0
79 2 0 55 105 73 84 2 0
2' 3'
HR SBP DBP MAP SOFLURAN NTG HR SBP DBP
79 109 77 88 2 0 71 96 63
77 95 60 72 1 0 75 94 60
80 93 62 72 1 0 77 93 61
77 83 54 64 2 0 75 81 54
84 89 64 72 2 0 83 84 62
79 89 67 74 2 0 79 89 67
64 92 61 71 2 0 65 89 59
60 91 58 69 2 0 61 80 59
64 100 66 77 2 0 62 82 56
63 91 59 70 2 0 63 86 61
67 94 61 72 2 0 65 89 59
69 87 62 70 2 0 69 87 62
60 92 60 71 2 0 59 83 60
61 91 66 74 2 0 57 83 57
61 79 54 62 2 0 61 79 54
70 83 57 66 2 0 66 98 67
74 86 62 70 2 0 63 92 53
60 93 58 70 2 0 53 98 67
62 91 63 72 2 0 62 91 63
55 90 62 71 2 0 53 82 56
4' 5
MAP SOFLURAN NTG HR SBP DBP MAP SOFLURAN NTG
74 2 0 72 94 60 71 0 0
71 1 0 84 93 59 70 2 0
72 1 0 77 93 61 72 1 0
63 0 0 76 90 62 71 0 0
69 1 0 83 84 61 69 0 0
74 2 0 77 83 57 66 2 0
69 2 0 65 90 55 67 2 0
66 2 0 60 94 55 68 2 0
65 2 0 63 83 59 67 2 0
69 2 0 63 82 56 65 2 0
69 2 0 65 100 55 70 2 0
70 2 0 65 92 53 66 2 0
68 2 0 59 93 50 64 2 0
66 2 0 59 92 53 66 2 0
62 2 0 65 99 54 69 2 0
77 2 0 63 80 50 60 2 0
66 2 0 68 69 44 52 2 0
77 2 0 58 89 59 69 2 0
72 2 0 60 80 59 66 2 0
65 2 0 54 77 50 60 2 0
5' 10'
HR SBP DBP MAP SOFLURAN NTG HR SBP DBP
66 101 60 73 0 0 64 86 62
74 88 57 67 1 0 73 88 57
74 91 59 70 1 0 73 90 55
73 81 55 64 0 0 72 83 56
86 83 59 67 0 0 86 83 59
78 95 56 69 1 0 63 92 44
62 80 59 66 1 0 65 87 62
59 88 83 71 2 0 69 90 62
65 90 68 75 2 0 59 95 64
67 91 62 72 2 0 57 89 62
76 83 60 68 2 0 61 88 61
76 82 56 65 1 0 66 82 54
58 94 57 69 2 0 63 89 62
63 94 57 69 2 0 53 89 63
61 92 56 68 2 0 62 88 61
67 83 60 68 2 0 61 91 63
74 84 63 70 2 0 55 87 66
62 86 62 70 2 0 59 89 62
64 96 56 69 1 0 57 88 61
55 86 62 70 2 0 60 92 60
15' 20
MAP SOFLURAN NTG HR SBP DBP MAP SOFLURAN NTG
70 0 0 73 106 89 95 0 0
67 0 0 68 92 54 67 0 0
67 1 0 72 90 55 67 0 0
65 0 0 72 86 58 67 0 0
67 0 0 90 90 60 70 0 0
60 1 0 61 85 62 70 1 0
70 2 0 55 92 56 68 1 0
71 2 0 59 86 62 70 1 0
74 2 0 57 84 63 70 1 0
71 2 0 60 96 56 69 1 0
70 1 0 63 86 54 65 1 0
63 1 0 67 87 62 70 1 0
71 2 0 72 96 56 69 1 0
72 2 0 73 83 60 68 1 0
70 2 0 72 85 55 65 1 0
72 2 0 66 98 73 81 2 0
73 2 0 61 99 66 73 2 0
71 2 0 55 99 59 72 1 0
70 2 0 59 94 64 74 2 0
71 2 0 57 85 61 69 1 0
0' 25'
HR SBP DBP MAP SOFLURAN NTG HR SBP DBP
74 94 63 73 0 0 72 108 79
66 90 56 67 0 0 73 93 60
70 89 55 66 0 0 72 76 48
69 86 60 69 0 0 66 86 60
89 89 60 70 0 0 88 87 61
64 89 61 70 1 0 78 96 56
62 92 60 71 1 0 62 89 62
61 84 59 67 1 0 59 87 62
54 88 61 70 2 0 65 82 54
62 87 62 70 2 0 67 86 54
63 89 62 71 2 0 76 89 62
61 91 85 74 2 0 76 96 56
72 87 66 73 2 0 58 95 64
73 86 54 65 1 0 63 84 63
72 91 63 72 2 0 61 90 62
66 87 62 70 2 0 67 86 62
65 88 61 70 2 0 74 92 44
61 96 56 69 1 0 62 92 56
62 89 63 72 2 0 64 85 62
63 86 57 67 1 0 55 96 64
30' 35
MAP SOFLURAN NTG HR SBP DBP MAP SOFLURAN NTG
89 0 0 78 102 67 79 0 0
71 0 0 62 99 73 82 2 0
57 0 0 68 85 54 65 0 0
69 0 0 66 86 60 69 0 0
70 0 0 86 85 63 70 0 0
69 0 0 62 87 58 68 1 0
71 1 0 59 83 53 63 0 0
70 0 0 65 84 57 66 0 0
63 0 0 67 93 58 70 1 0
65 0 0 86 83 60 68 0 0
71 0 0 76 83 53 63 0 0
69 0 0 68 86 57 67 0 0
74 1 0 66 85 55 65 0 0
70 0 0 68 84 58 67 0 0
71 0 0 70 91 66 74 1 0
70 0 0 66 85 55 65 0 0
60 0 0 65 83 58 66 0 0
68 0 0 69 86 57 67 0 0
70 1 0 65 87 62 70 1 0
75 2 0 57 86 53 64 0 0
5' 40'
HR SBP DBP MAP SOFLURAN NTG HR SBP DBP
75 108 73 85 0 0 77 103 69
61 92 61 71 2 0 62 90 64
68 86 54 65 0 0 68 87 54
62 86 61 69 0 0 67 87 62
83 84 63 70 0 0 81 82 63
79 78 56 63 0 0 78 92 44
65 94 53 67 0 0 62 96 56
61 81 54 63 0 0 59 87 62
62 96 50 65 0 0
63 87 62 70 1 0 67 90 62
65 83 60 68 0 0 76 86 54
69 89 61 70 0 0 76 95 64
59 87 61 70 0 0 58 96 56
57 86 57 67 0 0 63 89 62
61 100 55 70 1 0 61 84 63
66 84 58 67 0 0 67 88 61
63 96 56 69 0 0 74 86 62
53 89 67 74 0 0 62 82 54
62 91 66 74 0 0 64 92 56
53 93 58 70 0 0 55 89 62
45' 50
MAP SOFLURAN NTG HR SBP DBP MAP SOFLURAN NTG
87 0 0 78 98 66 77 0 0
73 1 0 74 107 76 86 2 0
65 0 0 66 87 54 65 0 0
70 0 0 64 99 70 80 1 0
69 0 0 77 83 62 69 0 0
60 0 0 65 89 63 72 1 0
69 0 0 61 85 55 65 1 0
70 0 0 62 88 61 70 1 0
71 0 0 60 91 63 72 1 0
65 0 0 53 96 56 69 1 0
74 0 0 57 87 62 70 1 0
69 0 0 55 87 66 73 1 0
71 0 0 58 86 54 65 1 0
70 0 0 66 89 62 71 1 0
70 0 0 67 96 56 69 1 0
70 0 0 74 88 61 70 1 0
63 0 0 62 92 60 71 1 0
68 0 0 64 84 63 70 1 0
71 0 0 60 86 62 70 1 0
0' 55'
HR SBP DBP MAP SOFLURAN NTG HR SBP DBP
74 103 71 82 0 0 66 100 70
64 92 61 71 1 0 62 103 72
67 86 55 65 0 0 65 86 58
61 86 58 67 1 0 63 85 59
79 82 62 69 0 0 84 63 45
69 98 73 81 2 0 62 86 53
66 99 59 72 1 0 56 83 59
68 85 61 69 1 0 57 87 62
68 87 62 70 1 0 63 83 58
66 85 62 70 1 0 62 89 59
68 91 85 74 1 0 54 85 55
70 86 62 70 1 0 57 84 57
65 87 62 70 1 0 62 93 58
69 83 60 68 1 0
66 98 73 81 2 0 67 83 53
58 99 59 72 1 0
61 85 61 69 1 0
64 82 56 65 1 0 61 83 60
60' 65
MAP SOFLURAN NTG HR SBP DBP MAP SOFLURAN NTG
80 0 0
82 0 0 70 117 76 88 0 0
67 0 0
68 1 0 56 85 60 68 0 0
51 0 0 78 143 94 110 2 0
64 1 0
67 1 0 58 83 58 66 1 0
70 1 0 60 84 57 66 1 0
66 1 0 63 83 53 63 1 0
69 1 0 63 87 62 70 1 0
65 1 0
66 1 0 60 90 60 70 1 0
70 1 0 65 93 50 64 1 0
63 1 0 69 94 56 69 1 0
68 1 0
5' 70'
HR SBP DBP MAP SOFLURAN NTG HR SBP DBP
56 86 61 69 0 0 65 89 63
86 114 81 92 2 0 83 104 73
61 87 58 68 1 0
63 85 55 65 1 0 62 83 59
62 90 63 72 1 0
75' 80
MAP SOFLURAN NTG HR SBP DBP MAP SOFLURAN NTG
72 0 0 59 109 81 90 2 0
83 1 0 82 95 63 74 0 0
67 1 0
0' 85'
HR SBP DBP MAP SOFLURAN NTG HR SBP DBP
62 104 76 85 2 0 57 96 71
79 84 59 67 0 0 78 87 62
90' 95
MAP SOFLURAN NTG HR SBP DBP MAP SOFLURAN NTG
79 2 0 58 93 69 77 2 1
70 0 0 76 91 85 74 0 0
5' 100'
HR SBP DBP MAP SOFLURAN NTG HR SBP DBP
62 91 65 74 2 2 62 89 63
78 94 65 75 0 0
105' 11
MAP SOFLURAN NTG HR SBP DBP MAP SOFLURAN NTG
72 2 2 62 91 64 73 2 2
10' 115'
HR SBP DBP MAP SOFLURAN NTG HR SBP DBP
63 100 70
74 120 83
86 107 76
81 111 81
81 111 81
56 108 73
66 99 73
61 106 76
56 103 68
61 98 71
59 117 80
61 115 83
55 114 77
59 101 68
56 100 66
60 81 53
55 117 80
68 88 63
59 123 84
55 102 69
120' AFTER NEOSTIGMINE
MAP HR SBP DBP MAP HR SBP DBP MAP
80 63 102 68 79 69 106 76 85
95 71 127 87 100 83 127 87 100
85 83 104 76 85 87 110 81 91
91 81 110 75 87 75 117 87 95
91 78 134 78 97 89 128 93 105
85 53 105 78 89 85 138 103 115
82 51 98 71 80 80 128 96 107
86 60 123 84 97 65 122 84 97
80 61 108 77 87 60 128 96 107
80 48 97 69 78 77 117 81 93
92 54 109 78 88 67 119 82 94
94 51 124 75 91 76 133 101 112
89 67 120 83 95 65 122 91 101
79 57 106 76 86 70 128 91 103
77 59 109 78 88 76 117 85 96
62 71 106 76 86 61 122 99 101
92 55 128 84 99 70 117 81 93
71 60 100 64 76 70 116 78 91
97 55 124 75 91 70 128 84 97
80 59 102 68 79 66 113 75 88
E 2' AFTER EXTUBATION
HYPOTENSION
HR SBP DBP MAP HR SBP DBP MAP
64 106 74 84 61 100 73 82 N
85 134 78 97 86 133 82 99 N
83 104 76 85 72 112 72 93 Y
76 116 87 95 73 100 70 80 N
83 110 66 81 84 110 67 81 N
67 118 78 91 71 100 70 80 N
59 116 78 91 70 106 76 86 N
51 118 78 91 71 110 75 87 N
64 109 74 86 61 101 63 76 N
51 128 89 102 58 101 67 78 N
68 131 96 108 64 103 68 80 N
55 132 88 103 88 127 86 100 N
56 134 104 114 63 100 66 77 N
56 137 104 115 80 121 87 98 N
63 132 98 109 70 115 83 94 N
59 110 72 85 76 124 75 91 N
59 134 92 106 69 101 68 79 N
61 113 80 91 74 103 59 74 N
50 127 86 100 55 109 78 88 N
51 112 79 90 56 121 89 98 N
2' 5'
HYPERTENSION ARRYTHMIAS TACHYCARDIA BRADYCARDIA ISCHAEMIA
N N N N N
N N N N N
N N N N N
N N N N N
N N N N N
N N N N N
N N N N N
N N N N N
N N N N N
N N N N N
N N N N N
N N N N N
N N N N N
N N N N N
N N N N N
N N N N N
N N N N N
N N N N N
N N N N N
N N N N N
INTRAOPERATIVE PROBLEMS
DURATION OF SURGERY OPERATING FIELD POST OP SEDATION SCORE ANALGESIC REQUEST
(Hrs after extubation)
65 GOOD 3 0
70 GOOD 3 0
65 GOOD 3 0
115 GOOD 4 0
105 EXCELLENT 4 0
65 GOOD 4 2
70 GOOD 4 0
75 GOOD 4 0
45 GOOD 4 0
80 EXCELLENT 4 1
70 EXCELLENT 3 0
65 GOOD 4 0
75 EXCELLENT 2 0
55 GOOD 4 3
75 EXCELLENT 3 0
60 EXCELLENT 3 0
70 EXCELLENT 3 0
60 GOOD 4 0
60 GOOD 3 1
65 GOOD 3 0
6.00 pm 
8
8
8
8
8
8
8
8
8
8
8
7
8
8
8
8
7
7
8
8
10
9
9
9
9
9
9
8
10
9
9
10
9
9
9
10
10
9
PADSS 
6.00 am 1st POD
9
9
